Aramon Neuro-Medical develops a new drug formulation administered with a medical device that will be used in patients who are resistant to oral dopamine treatment. This is a problem that currently affects about 10% of Parkinson's patients and is considered to be one of the largest unmet medical needs in the field of Parkinson's disease.

Aramon’s compound is a short-acting DA, which physicochemical properties and outstanding potency make it an excellent candidate for continuous subcutaneous (sc) infusion at low doses and volumes. It can be administered by a portable minipump or a patch-pump with daily doses of only about 1mg. This permits a ‘tailor-made’ individualized treatment. It also has strong 5-HT1A agonist effects with anti-dyskinetic properties.

Significant and quite relevant improvement in ‘OFF’ time and in dyskinesias has been reported in prospective randomized trials (compared to high-dosed oral L-DOPA) and in this way a sc infusion of the compound avoids the risks of percutaneous enterogastrostomy (PEG), which is necessary for a continuous infusion of L-DOPA, and/or brain surgery (‘Deep Brain Stimulation’, DBS).